Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 4,15 M
EBIT 2016 -22,9 M
Net income 2016 -22,6 M
Debt 2016 4,53 M
Yield 2016 -
Sales 2017 7,15 M
EBIT 2017 -22,9 M
Net income 2017 -22,8 M
Debt 2017 11,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 32,1x
EV / Sales2017 19,5x
Capitalization 129 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
07/07 ONXEO COLLABORATES WITH THE ROYAL CO : Onxeo samarbejder med Royal College of Su..
07/05 ONXEO : Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP..
07/04 ONXEO RECEIVES USPTO NOTICE OF ALLOW : Onxeo modtager “Notice of Allowance..
06/27 ONXEO ADVANCES DEVELOPMENT PLAN FOR : Onxeo offentliggør udviklingsplan for det..
06/27 ONXEO : advances development plan for first-in-class signal interfering DNA comp..
06/03 ONXEO : Announces Development of Beleodaq Oral Formulation Opening New Opportuni..
06/02 ONXEO ANNOUNCES DEVELOPMENT OF BELEO : Onxeo offentliggør udviklingen af en oral..
05/02 PUBLICATION OF 2015 REFERENCE DOCUME : Offentliggørelse af Reference Document fo..
04/28 ONXEO : First Quarter 2016 Financial information and Business Update
04/06 ONXEO : Passing on Onxeo’s Extraordinary and Ordinary General Meeting // D..
More news
Sector news : Pharmaceuticals - NEC
04:52pDJASTRAZENECA : 2Q 2016 -- Forecast
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 9,00 €
Spread / Average Target 190%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Graham K. Dixon Chief Scientific Officer
David Horn Solomon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA141
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results